M&A Deal Summary |
|
|---|---|
| Date | 2021-07-27 |
| Target | AFFiRiS - Specific Active Immunotherapy anti-alpha-synuclein Programs |
| Sector | Life Science |
| Buyer(s) | AC Immune |
| Sellers(s) | AFFiRiS |
| Deal Type | Divestiture |
| Deal Value | 59M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Sector | Life Science |
| Employees | 125 |
| Revenue | 15M USD (2020) |
AC Immune is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and NeuroOrphan indications driven by misfolded proteins. The Company's two clinically validated technology platforms, SupraAntigen and Morphomer, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune is based in Lausanne, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (Austria) | 1 of 1 |
| Year (2021) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
AFFiRiS is a clinical-stage biopharmaceutical company that pursues the ultimate aim to improve the lives of patients suffering from neurodegenerative diseases. AFFiRiS have a broad portfolio of immunotherapy candidates which are currently in clinical trials or in preclinical development for a variety of neurodegenerative diseases; these include Parkinson’s disease, multiple system atrophy (MSA), dementia with Lewy bodies (DLB), and Huntington’s disease (mutHTT). AFFiRiS was founded in 2003 and is based in Vienna, Austria.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (Austria) | 1 of 1 |
| Year (2021) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
